Back to News
Market Impact: 0.25
Firefly Collaborates With NeuroSigma On Promoting Device For Pediatric ADHD; Stock Surges Over 25%
Source: Nasdaq
Healthcare & BiotechArtificial IntelligenceTechnology & InnovationProduct Launches
Firefly Neuroscience announced a strategic partnership with NeuroSigma to expand access to the Monarch external trigeminal nerve stimulation (eTNS) system for pediatric attention-deficit/hyperactivity disorder. The collaboration is a positive commercial-access initiative for Firefly's AI precision-neuroscience platform, though the article provides no financial terms, sales targets, or revenue impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AIFF0.55
More News
- Great Bond Shakeout Locks In a 5% World ‘Until Something Breaks’
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Boom or bust? The case for and against panicking about 5% yields
- Bond market alarms are ringing on Wall Street. Here's what's ahead
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Bonds Stabilize as Oil Retreats